Ppt hemolytic disease of the newborn & fetus
Upcoming SlideShare
Loading in...5
×
 

Ppt hemolytic disease of the newborn & fetus

on

  • 4,621 views

PPT for Hemolytic Disease of the Newborn & Fetus

PPT for Hemolytic Disease of the Newborn & Fetus

Statistics

Views

Total Views
4,621
Views on SlideShare
4,621
Embed Views
0

Actions

Likes
0
Downloads
134
Comments
0

0 Embeds 0

No embeds

Accessibility

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

    Ppt hemolytic disease of the newborn & fetus Ppt hemolytic disease of the newborn & fetus Presentation Transcript

    • Chapter 13Hemolytic Disease of the Fetus and Newborn Mosby items and derived items © 2009 by Mosby, Inc., an affiliate of Elsevier Inc. 1 Some material was previously published.
    • Hemolytic Disease of the Fetus and Newborn (HDFN) A disorder of the fetus or newborn in which fetal red blood cells are destroyed by maternal IgG antibodies The IgG antibodies cross the placenta and shorten red cell survival The premature red cell destruction results in disease varying from mild anemia to death in utero Mosby items and derived items © 2009 by Mosby, Inc., an affiliate of Elsevier Inc. 2 Some material was previously published.
    • Etiology in Fetus The mother is exposed during first pregnancy In a subsequent pregnancy, IgG antibodies cross the placenta The antigens bind to fetal cells and red cells are destroyed, liberating hemoglobin The hemoglobin is metabolized to indirect hemoglobin Anemia occurs, which can lead to death Mosby items and derived items © 2009 by Mosby, Inc., an affiliate of Elsevier Inc. 3 Some material was previously published.
    • Etiology in Newborn After delivery, red cell destruction continues Indirect bilirubin is still being released Newborn liver does not produce glucuronyl transferase to process the indirect bilirubin High indirect bilirubin levels result in jaundice and also can cause brain damage, deafness, mental retardation, or death Mosby items and derived items © 2009 by Mosby, Inc., an affiliate of Elsevier Inc. 4 Some material was previously published.
    • Figure 13-1From Ortho Diagnostics: Blood group antigens and antibodies as applied to hemolytic disease of the fetus and newborn, Raritan, NJ, 1968, Ortho Diagnostics. Mosby items and derived items © 2009 by Mosby, Inc., an affiliate of Elsevier Inc. 5 Some material was previously published.
    • Rh HDFN Anti-D responsible for most severe cases of HDFN Alloimmunization occurs during first pregnancy if baby is D-positive but rarely results in clinical symptoms Following antibody production, subsequent pregnancies with a D-positive infant are affected to varying degrees Rh immune globulin (RhIG), introduced in 1968, dramatically reduced the incidence of Rh HDFN Mosby items and derived items © 2009 by Mosby, Inc., an affiliate of Elsevier Inc. 6 Some material was previously published.
    • ABO HDFN More common, but most cases are subclinical and do not need treatment If jaundice develops, mild cases can be treated by phototherapy Usually group O mothers with group A or B infants Unlike D, can affect first pregnancy Mosby items and derived items © 2009 by Mosby, Inc., an affiliate of Elsevier Inc. 7 Some material was previously published.
    • Alloantibodies Causing HDFN Any IgG antibody is capable of causing HDFN if the fetal red cells possess antigens that the mother lacks Anti-c is the second most common cause of HDFN; can be in combination with anti- D Next is anti-K Mosby items and derived items © 2009 by Mosby, Inc., an affiliate of Elsevier Inc. 8 Some material was previously published.
    • Table 13-1Mosby items and derived items © 2009 by Mosby, Inc., an affiliate of Elsevier Inc. 9 Some material was previously published.
    • Prediction of HDFN Prenatal testing should be done D-negative mothers need to be identified Mothers who have antibodies capable of causing HDFN need to be identified Maternal history is also important Mosby items and derived items © 2009 by Mosby, Inc., an affiliate of Elsevier Inc. 10 Some material was previously published.
    • Box 13-1Mosby items and derived items © 2009 by Mosby, Inc., an affiliate of Elsevier Inc. 11 Some material was previously published.
    • Antibody Titration Commonly used to predict severity of HDFN Titer done early in pregnancy Repeated at 16 to 22 weeks and repeated at 1- to 4-week intervals A twofold rise in titer is an indication for further monitoring To ensure significance, titers should be done using the same method and cells Mosby items and derived items © 2009 by Mosby, Inc., an affiliate of Elsevier Inc. 12 Some material was previously published.
    • Amniocentesis Measurement of bilirubin in amniotic fluid can help indicate level of red cell destruction Aspirated fluid is scanned on a spectrophotometer from 350 to 700 nm. The change in optical density above the baseline 450 nm is plotted on a Liley graph Mosby items and derived items © 2009 by Mosby, Inc., an affiliate of Elsevier Inc. 13 Some material was previously published.
    • Figure 13-2From Mollison PL, Engelfriet CP, Conteras M: Blood transfusion in clinical medicine, ed 9, London, 1993, Blackwell Science. Mosby items and derived items © 2009 by Mosby, Inc., an affiliate of Elsevier Inc. 14 Some material was previously published.
    • Liley GraphThe Liley graph defines three zones to estimate severity: Correlates with severe if results are in the top zone Mid zone correlates with moderate Bottom zone correlates with mild HDFN Mosby items and derived items © 2009 by Mosby, Inc., an affiliate of Elsevier Inc. 15 Some material was previously published.
    • Interpretation of Liley Graph Based on amniotic fluid analysis Three alternatives exist: - Allow pregnancy to continue - Perform intrauterine transfusion - Induce labor If labor is to be induced, L/S ratio needs to be done to determine fetal lung maturity Mosby items and derived items © 2009 by Mosby, Inc., an affiliate of Elsevier Inc. 16 Some material was previously published.
    • Postpartum Testing Collect sample of cord blood Sample should be labeled and stored up to 7 days All infants born to D-negative mothers should be tested for D, including weak D D-negative mothers of D-positive infants, including weak D-positive infants, are candidates for RhIG Mosby items and derived items © 2009 by Mosby, Inc., an affiliate of Elsevier Inc. 17 Some material was previously published.
    • Testing on Infants with Suspected HDFN A diagnosis is based on medical history, physical examination, and lab testing on mother and infant Tests to be performed:  ABO only forward type  D testing  Direct antiglobulin test if positive elution is done  Eluate should be tested against A, B, and O cells  Negative with all cells, low-frequency antibody Mosby items and derived items © 2009 by Mosby, Inc., an affiliate of Elsevier Inc. 18 Some material was previously published.
    • Prevention of HDFN RhIG provides protection for 30 mL of fetal whole blood A 300-µg dose is routinely administered to D- negative mothers antepartum at 28 weeks’ gestation Also administered to D-negative mothers after amniocentesis, abortion, termination of ectopic pregnancy, chorionic villus sampling, percutaneous umbilical blood sampling (PUBS), or abdominal trauma Mosby items and derived items © 2009 by Mosby, Inc., an affiliate of Elsevier Inc. 19 Some material was previously published.
    • Postpartum Administration Cord blood from all infants born to D- negative women should be tested for D antigen Any D-negative woman who delivers a D- positive infant is given a full dose of RhIG within 72 hours of delivery There should be a history of negative antibody screen during the current pregnancy Mosby items and derived items © 2009 by Mosby, Inc., an affiliate of Elsevier Inc. 20 Some material was previously published.
    • Screening for Fetomaternal Hemorrhage (FMH) If during delivery a woman exceeds an FMH greater than 30 mL of D-positive fetal cells, it is essential that she receive more than one dose of RhIG Currently most frequently used method to screen for FMH is the rosette test Mosby items and derived items © 2009 by Mosby, Inc., an affiliate of Elsevier Inc. 21 Some material was previously published.
    • Figure 13-4 Courtesy Gamma Biologicals, Houston.Mosby items and derived items © 2009 by Mosby, Inc., an affiliate of Elsevier Inc. 22 Some material was previously published.
    • Quantifying FMH Kleihauer-Betke acid elution is the method most frequently used to quantify the number of fetal cells in the mother’s circulation Mosby items and derived items © 2009 by Mosby, Inc., an affiliate of Elsevier Inc. 23 Some material was previously published.
    • Figure 13-5Mosby items and derived items © 2009 by Mosby, Inc., an affiliate of Elsevier Inc. 24 Some material was previously published.
    • Treatment of HDFN In utero treatment includes intrauterine transfusions to correct anemia Recently PUBS has been used to transfuse directly into the umbilical vein Blood for intrauterine transfusion should be group O, D-negative RBCs less than 7 days old, irradiated, cytomegalovirus (CMV) negative, and hemoglobin S negative Donor cells are crossmatched with mother’s serum Mosby items and derived items © 2009 by Mosby, Inc., an affiliate of Elsevier Inc. 25 Some material was previously published.
    • Postpartum Treatment Phototherapy: Infants are exposed to blue light in the 420- to 475-nm range If infant fails to respond, exchange transfusion is needed For exchange transfusion, ABO and D testing is done on infant. Mother’s plasma is used for antibody screen CMV and hemoglobin S negative blood used Mosby items and derived items © 2009 by Mosby, Inc., an affiliate of Elsevier Inc. 26 Some material was previously published.
    • Box 13-5Mosby items and derived items © 2009 by Mosby, Inc., an affiliate of Elsevier Inc. 27 Some material was previously published.